BioMarin reports record Q4 revenues $537.5M (+19% YoY); guides 2023 total rev $2.375-2.5B

BIOMARIN PHARMACEUTICAL INC

2022-FY EPS reported $0.75 revenue$2,096,039,000

Q4 total revenues $537.5M, up 19% YoY; full year $2.096B, up 14%.
GAAP net loss improved to $0.2M in Q4 from $57.9M loss; full year net income $141.6M.
VOXZOGO full year revenues $169.1M, up from $5.9M in 2021; 1,264 children treated as of Jan 2023.
2023 guidance: total rev $2.375-2.5B, GAAP net income $155-205M, non-GAAP EPS $1.80-2.05.
ROCTAVIAN 2023 revenue guidance $100-200M; FDA PDUFA date March 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOMARIN PHARMACEUTICAL INC updated its fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).

Period: fourth quarter and full year ended December 31, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 27, 2023, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2022. The Company’s press release issued on February 27, 2023 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-23-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.